

**DATES:** Comments regarding this information collection are best assured of having their full effect if received within 60 days of the date of this publication.

**FOR FURTHER INFORMATION CONTACT:** To obtain a copy of the data collection plans and instruments, submit comments in writing, or request more information on the proposed project, contact Candace Maynard, Branch Chief, Cancer Information Service Branch, CISB/OCPL, 9609 Medical Center Drive, Rockville, MD 20850, or call non-toll-free number 240–276–6657 or email your request, including your address to: [deatonc@mail.nih.gov](mailto:deatonc@mail.nih.gov). Formal requests for additional plans and instruments must be requested in writing.

**SUPPLEMENTARY INFORMATION:** Section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995 requires written comments and/or suggestions from the public, and affected agencies are invited to address one or more of the following points: (1) Whether the proposed collection of information is necessary

for the proper performance of the function of the agency, including whether the information will have practical utility; (2) The accuracy of the agency’s estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; (3) Ways to enhance the quality, utility, and clarity of the information to be collected; and (4) Ways to minimize the burden of the collection of information on those who are to respond, including the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology.

*Proposed Collection Title:* Collection of Customer Service, Demographic, and Smoking/Tobacco use Information from the National Cancer Institute’s (NCI) Cancer Information Service (CIS), 0925–0208, Expiration Date 03/31/2025, REVISION, National Cancer Institute (NCI), National Institutes of Health (NIH).

*Need and Use of Information Collection:* The National Cancer

Institute (NCI) currently collects (1) customer service and demographic information from clients of the Cancer Information Service (CIS) to properly plan, implement, and evaluate cancer education efforts, including assessing the extent by which the CIS reaches and impacts underserved populations; (2) smoking/tobacco use behavior of individuals seeking NCI’s smoking cessation assistance through the CIS to provide smoking cessation services tailored to the individual client’s needs and track their smoking behavior at follow up. This is a request for OMB to approve a revised submission for an additional three years to provide ongoing customer service collection of demographic information and collection of brief customer satisfaction questions from NCI Cancer Information Service Clients for the purpose of program planning and evaluation.

OMB approval is requested for 3 years. Respondents’ only cost is their time. The total estimated annualized burden hours are 6,343.

**ESTIMATED ANNUALIZED BURDEN HOURS**

Form name	Category of respondent	Number of respondents	Number of responses per respondent	Average time per response (in hours)	Total annual burden hours
Demographic & Customer Satisfaction Questions (Appendix 1A or 1AB).	Individuals .....	15,754	1	3/60	788
Demographic & Customer Satisfaction Questions (Appendix 1B).	Individuals .....	17,589	1	2/60	586
Smoking Cessation “Intake” Questions (Appendix 1C).	Individuals .....	8,839	1	6/60	884
Smoking Call Backs (Appendix 1D) .....	Individuals .....	8,840	1	4/60	589
VA Call Backs (Appendix 1E) .....	Individuals .....	26,055	1	4/60	1,737
Cancer Info Call Backs (Appendix 1F) .....	Individuals .....	1,841	1	4/60	123
Email Intake Form (Appendix 2) .....	Individuals .....	9,740	1	10/60	1,623
Demographic & Customer Satisfaction Questions (Appendix 9).	Individuals .....	400	1	2/60	13
<b>Totals .....</b>	<b>.....</b>	<b>.....</b>	<b>113,191</b>	<b>.....</b>	<b>6,343</b>

Dated: October 2, 2024.

**Diane Kreinbrink,**

*Project Clearance Liaison, National Cancer Institute, National Institutes of Health.*

[FR Doc. 2024–23127 Filed 10–4–24; 8:45 am]

**BILLING CODE 4140–01–P**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**National Institutes of Health**

**Prospective Grant of an Exclusive Patent License: Anti-KK–LC–1 T Cell Receptors**

**AGENCY:** National Institutes of Health, HHS.

**ACTION:** Notice.

**SUMMARY:** The National Cancer Institute, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the

Patents and Patent Applications listed in the Supplementary Information section of this notice to T-Cure Biosciences, Inc. (“T-Cure”) located in Calabasas, California.

**DATES:** Only written comments and/or applications for a license which are received by the National Cancer Institute’s Technology Transfer Center on or before October 22, 2024 will be considered.

**ADDRESSES:** Requests for copies of the patent application, inquiries, and comments relating to the contemplated an Exclusive Patent License should be directed to: Suna Gulay French, Ph.D., Technology Transfer Manager, NCI

Technology Transfer Center, 9609 Medical Center Drive, RM 3W-204, MSC 9702, Bethesda, MD 20892-9702 (for business mail), Rockville, MD 20850-9702; Telephone: (240)-276-5530; Email: [suna.gulay@nih.gov](mailto:suna.gulay@nih.gov).

#### SUPPLEMENTARY INFORMATION:

##### Intellectual Property

1. United States Provisional Patent Application No. 62/327,529, filed April 26, 2016 and entitled "Anti-KK-LC-1 T Cell Receptors" [HHS Reference No. E-153-2016-0-US-01];

2. PCT Patent Application No. PCT/US2017/027865, filed April 17, 2017 and entitled "Anti-KK-LC-1 T Cell Receptors" [HHS Reference No. E-153-2016-0-PCT-02];

3. Australian Patent No. 2017258745, issued July 14, 2022 and entitled "Anti-KK-LC-1 T Cell Receptors" [HHS Reference No. E-153-2016-0-AU-03];

4. Canadian Patent Application No. 3021898, filed April 17, 2017 and entitled "Anti-KK-LC-1 T Cell Receptors" [HHS Reference No. E-153-2016-0-CA-04];

5. European Patent No. 3448882, issued November 24, 2021 and entitled "Anti-KK-LC-1 T Cell Receptors" [HHS Reference No. E-153-2016-0-EP-05];

a. Validated in the following jurisdictions: CH, DE, BE, DK, ES, FI, FR, GB, IE, IT, NL, NO and SE.

6. U.S. Patent No. 11,352,410, issued June 7, 2022 and entitled "Anti-KK-LC-1 T Cell Receptors" [HHS Reference No. E-153-2016-0-US-06].

The patent rights in these inventions have been assigned and/or exclusively licensed to the government of the United States of America.

The prospective exclusive license territory may be worldwide and the field of use may be limited to the following:

"1. Development, manufacture, and commercialization of autologous T cell therapy products, including T cells with stem-like properties, engineered via retrovirus-mediated gene transfer to express T cell receptors reactive to Kita-Kyushu Lung Cancer Antigen 1 (KK-LC-1), as claimed in the Licensed Patent Rights; such products to be developed for treatment of patients carrying HLA-A\*01:01 histocompatibility haplotype, and diagnosed with a cancer expressing KK-LC-1 protein ("KK-LC-1 Targeting TCR-T Products").

2. Development, manufacture, and commercialization of a combination therapy for the treatment of KK-LC-1 expressing human cancers, independent of their HLA phenotype, wherein the treatment comprises:

a. Modification of the patient's tumor using Licensee's proprietary technology

to express the HLA-A\*01:01 restriction element, and

b. Treatment with the KK-LC-1 Targeting TCR-T Products.

For the avoidance of doubt, specifically excluded from these Fields of Use are Natural Killer cell therapy products engineered via viral vectors (including lentivirus or retrovirus) to express the TCR(s) claimed in the Licensed Patent Rights."

This technology discloses isolated T cell receptors (TCR) reactive to the Kita-Kyushu lung cancer antigen 1 (KK-LC-1) within the context of human leukocyte antigen (HLA) A\*01:01. KK-LC-1 is expressed by various epithelial cancers including carcinomas of the bladder, cervix, stomach, breast, lung, and pancreas. Due to its minimal expression in normal tissues, this antigen may be targeted on KK-LC-1-expressing tumors with minimal normal tissue toxicity.

This notice is made in accordance with 35 U.S.C. 209 and 37 CFR part 404. The prospective exclusive license will be royalty bearing, and the prospective exclusive license may be granted unless within fifteen (15) days from the date of this published notice, the National Cancer Institute receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR part 404.

In response to this Notice, the public may file comments or objections. Comments and objections, other than those in the form of a license application, will not be treated confidentially, and may be made publicly available.

License applications submitted in response to this Notice will be presumed to contain business confidential information and any release of information in these license applications will be made only as required and upon a request under the Freedom of Information Act, 5 U.S.C. 552.

Dated: October 1, 2024.

**Richard U. Rodriguez,**

*Associate Director, Technology Transfer Center, National Cancer Institute.*

[FR Doc. 2024-23029 Filed 10-4-24; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Center for Scientific Review; Notice of Closed Meetings

Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* Biological Chemistry and Macromolecular Biophysics Integrated Review Group; Drug Discovery and Molecular Pharmacology B Study Section.

*Date:* October 31-November 1, 2024.

*Time:* 8:00 a.m. to 7:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).

*Contact Person:* Razvan Cornea, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 904L, Bethesda, MD 20892, (301) 480-1955, [cornearl@csr.nih.gov](mailto:cornearl@csr.nih.gov).

*Name of Committee:* Center for Scientific Review Special Emphasis Panel; Imaging and Bioengineering Technology for Visual Systems (IBV).

*Date:* November 4-5, 2024.

*Time:* 8:00 a.m. to 7:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* The Watergate, 2650 Virginia Avenue NW, Washington, DC 20037.

*Contact Person:* Susan Gillmor, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (240) 762-3076, [susan.gillmor@nih.gov](mailto:susan.gillmor@nih.gov).

*Name of Committee:* Center for Scientific Review Special Emphasis Panel; Fellowships: Learning, Memory, Language, Communication and Related Neuroscience.

*Date:* November 4-5, 2024.

*Time:* 8:00 a.m. to 8:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Canopy by Hilton, 940 Rose Avenue, North Bethesda, MD 20852.

*Contact Person:* Alexei Kondratyev, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5200, MSC 7846, Bethesda, MD 20892, 301-435-1785 [kondratyevad@csr.nih.gov](mailto:kondratyevad@csr.nih.gov).